Myriad Genetics Inc
XHAM:MYD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2), the stock would be worth €6.67 (63% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.2 | €4.08 |
0%
|
| 3-Year Average | 2 | €6.67 |
+63%
|
| 5-Year Average | 2 | €6.72 |
+65%
|
| Industry Average | 4.6 | €15.2 |
+272%
|
| Country Average | 2.5 | €8.35 |
+104%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Myriad Genetics Inc
XHAM:MYD
|
452.5m EUR | 1.2 | -1.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | -106.9 | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 21.1 | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 7.1 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 5.9 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 2.5 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 6.5 | 36.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 2.2 | 29.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Myriad Genetics Inc
Glance View
Nestled at the crossroads of healthcare innovation and genetic science, Myriad Genetics Inc. has been a pioneering force in molecular diagnostics for over three decades. Founded in 1991 and headquartered in Salt Lake City, Utah, the company carved out its niche by focusing on predictive medicine—an area that seeks to forecast disease risk based on genetic predispositions. At the heart of Myriad's operations is its robust arsenal of genetic tests that identify individuals' risk for various conditions, including cancer, cardiovascular illnesses, and other hereditary disorders. This approach not only aids early intervention and personalized treatment plans but also empowers patients with crucial information about their genetic backgrounds. Myriad's business model orbits around the research, development, and commercialization of these high-impact diagnostic tests. Revenue streams flow primarily from the sale of its flagship products, which include the BRACAnalysis CDx test for assessing breast and ovarian cancer risk and various other hereditary cancer tests that evaluate susceptibility to prostate and colorectal cancers. Further, Myriad advances its impact through collaborations with healthcare providers, folding clinical research findings into broader medical practice. In a world where healthcare is increasingly leaning towards precision medicine, Myriad Genetics stands as a testament to the value of science-led business strategies, sustaining its growth through a clear focus on marrying advanced genomic knowledge with accessible and actionable clinical applications.
